Selective PDE4D Inhibitors Avoid Vomiting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE4 inhibitors used for treating depression and Alzheimer's disease often cause vomiting side effects, limiting their therapeutic effectiveness and safety.
Innovation Solution
Development of non-competitive phosphodiesterase 4 inhibitors, specifically compounds represented by formulas (II) and (III), which are designed to have higher inhibitory activity against the PDE4D subtype without causing vomiting, synthesized through a method involving 3-substituted-4-methoxy toluene and heterocyclic amines, demonstrating improved safety and efficacy in animal models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation PDE4 inhibitor (rolipram) is used, then antidepressant effect is achieved, but vomiting side effects occur
Solution Approach 1:
The patent segments the PDE4 enzyme into four distinct isoforms (PDE4A, PDE4B, PDE4C, PDE4D) encoded by separate genes. The invention selectively targets PDE4D isoform while sparing other isoforms, thereby achieving antidepressant effects without the vomiting side effects associated with non-selective PDE4 inhibition. This isoform-specific approach allows differential therapeutic outcomes.
Solution Approach 2:
The patent applies local quality by designing compounds with specific molecular structures (formulas I and II containing heterocyclic amine cores with particular substituent patterns) that confer selective affinity for PDE4D isoform. The compounds exhibit different binding characteristics toward different PDE4 isoforms, achieving localized inhibition of PDE4D while maintaining normal function of other isoforms to avoid harmful effects.
2Reliability
If second-generation PDE4 inhibitor is used, then therapeutic effect is improved, but vomiting side effects still occur
Solution Approach 1:
The patent continues the segmentation strategy by further refining isoform selectivity within the PDE4 family. Second-generation compounds in the patent demonstrate enhanced selectivity for PDE4D over other PDE4 isoforms through optimized molecular structures, achieving better therapeutic effects while maintaining the goal of reducing vomiting side effects through selective inhibition.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters of the inhibitor compounds (such as substituent types, positions, and configurations in formulas I and II) to optimize the balance between therapeutic efficacy and side effect profile. These structural parameter adjustments enhance PDE4D selectivity and improve the therapeutic index.
3Reliability
If PDE4 inhibitor is designed to have high inhibitory activity, then antidepressant and cognitive effects are enhanced, but vomiting side effects increase
Solution Approach 1:
The patent resolves this contradiction by segmenting the inhibitory activity across different PDE4 isoforms. The compounds demonstrate high overall PDE4 inhibitory activity through potent inhibition of PDE4D isoform, while the selective nature of PDE4D inhibition prevents the vomiting side effects that occur with broad-spectrum PDE4 inhibition. This segmented approach allows high activity without proportional increase in harmful effects.
Solution Approach 2:
The patent applies local quality by concentrating inhibitory potency specifically at the PDE4D isoform through carefully designed molecular structures. The compounds exhibit localized high activity toward PDE4D while showing reduced activity toward other PDE4 isoforms, thereby achieving enhanced antidepressant and cognitive effects without the vomiting side effects associated with non-selective high-potency inhibitors.
Data Source
AI summary
The present invention relates to a kind of Phosphodiesterase 4 inhibitors without vomiting, which is compounds or a prodrugs or solvates represented by formula (I), R1 is an independent methoxy, bromine and substituted aryl; X is an optionally substituted six-membered heterocyclic ring; Y is -(CH2)n-, -NH(CH2)n-, and-NH(CH2)n-O-, wherein n is any value among 0, 1, 2 and 3; Z is an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring. The present invention is relates to a kind of Phosphodiesterase 4 inhibitors without vomiting, which is a novel biphenyl series PDE4D inhibitor, and can be applied to treat depression and Alzheimer's disease, improve cognitive ability and avoid vomiting.